Cargando…

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections

Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections. As new antibiotic therapies come on the market, limited data exist about the effectiveness of such treatments in clinical practice. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caffrey, Aisling R., Appaneal, Haley J., Liao, J. Xin, Piehl, Emily C., Lopes, Vrishali, Dillon, Ryan J., Puzniak, Laura A., LaPlante, Kerry L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137796/ https://www.ncbi.nlm.nih.gov/pubmed/35625270 http://dx.doi.org/10.3390/antibiotics11050626

Ejemplares similares

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa
por: Appaneal, Haley J., et al.
Publicado: (2022)

Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling R., et al.
Publicado: (2022)

1628. Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
por: Caffrey, Aisling, et al.
Publicado: (2020)

1610. Epidemiology and Treatment Heterogeneity in Acinetobacter baumanii Infections
por: Caffrey, Aisling, et al.
Publicado: (2020)

1585. Stenotrophomonas maltophilia Infections and Approaches to Treatment
por: Caffrey, Aisling, et al.
Publicado: (2020)

846. Trends in Acinetobacter baumanii Antibiotic Resistance Rates
por: Caffrey, Aisling, et al.
Publicado: (2020)

847. Trends in Stenotrophomonas maltophilia Antibiotic Resistance Rates
por: Caffrey, Aisling, et al.
Publicado: (2020)

Antibiotic Prescribing in Outpatient Settings: Rural Patients Are More Likely to Receive Fluoroquinolones and Longer Antibiotic Courses
por: Appaneal, Haley J., et al.
Publicado: (2023)

1067. Comparative Effectiveness of Nafcillin or Oxacillin, Cefazolin, and Piperacillin/Tazobactam in Methicillin-Sensitive Staphylococcus aureus Bacteremia
por: Beganovic, Maya, et al.
Publicado: (2018)

470. Concomitant Antibiotic Use and Death Among a National Cohort of Veterans With Clostridium difficile Infection (CDI)
por: Appaneal, Haley, et al.
Publicado: (2018)

Decreasing Antibiotic Resistance Trends Nationally in Gram-Negative Bacteria Across United States Veterans Affairs Medical Centers, 2011–2020
por: Liao, J. Xin, et al.
Publicado: (2023)

1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)
por: Dillon, Ryan J, et al.
Publicado: (2020)

1238. A National Comparison of Antibiograms Between Veterans Affairs Long-Term Care Facilities and Affiliated Hospitals
por: Tolg, Maria-Stephanie, et al.
Publicado: (2018)

2049. Trends in Antibiotic Use and Antibiotic Resistance among Veterans Affairs Community Living Centers from 2011 to 2017
por: Appaneal, Haley, et al.
Publicado: (2019)

2012. Trends in Microbiological Culture Collection Across Veterans Affairs Medical Centers and Community Living Centers, 2010 to 2017
por: Appaneal, Haley, et al.
Publicado: (2019)

1219. Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

2406. “Real-world” Treatment of Multidrug-Resistant (MDR) or Extensively Drug-Resistant (XDR) P. aeruginosa Infections With Ceftolozane/Tazobactam (C/T) vs. a Polymyxin or Aminoglycoside (Poly/AG)-based Regimen: A Multicenter Comparative Effectiveness Study
por: Pogue, Jason M, et al.
Publicado: (2018)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
por: Khankhel, Z. S., et al.
Publicado: (2022)

Real-world use of ceftolozane/tazobactam: a systematic literature review
por: Puzniak, Laura, et al.
Publicado: (2021)

Poor clinical outcomes associated with suboptimal antibiotic treatment among older long-term care facility residents with urinary tract infection: a retrospective cohort study
por: Appaneal, Haley J., et al.
Publicado: (2021)

A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Hart, Delaney E, et al.
Publicado: (2021)

2274. Comparison of Clinical Outcomes in Patients with Extensively Drug-Resistant Pseudomonas aeruginosa Pneumonia Treated with Aminoglycosides vs. Ceftolozane/Tazobactam
por: Pervin, Najwa, et al.
Publicado: (2019)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
por: Puzniak, Laura, et al.
Publicado: (2021)

Post-Discharge Antibiotic Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections
por: Caffrey, Aisling, et al.
Publicado: (2017)

In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients
por: Dassner, Aimee M., et al.
Publicado: (2016)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen
por: Patel, Ursula C., et al.
Publicado: (2016)

2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
por: Hart, Delaney E, et al.
Publicado: (2019)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
por: Sanders, James, et al.
Publicado: (2021)

Impact of Vancomycin-Associated Acute Kidney Injury on Patient Outcomes in MRSA Bacteremia
por: Luther, Megan, et al.
Publicado: (2017)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
por: Gallagher, Jason C, et al.
Publicado: (2018)

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2019)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4pjrdpuictum6rcof4rfrt6pdq